ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,214.50
-0.10%
S&P ASX All Technology
3,562.20
0.19%
Brent Oil
78.695
0.00%
US Dollar vs AUD
1.48126
0.00%
Bitcoin
63,025.08
0.92%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Aligos Therapeutics Inc (ALGS) Share Price

Aligos Therapeutics Inc

Aligos Therapeutics Inc (ALGS)

NASDAQ
7.62
0.73
(10.60%)
Closed 13 October 7:00AM
Delayed by 15 minutes
7.41
-0.21
(-2.76%)
After Hours: 10:59AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
7.62
Bid
6.93
Offer
7.59
Volume
62,684
6.85 Day's Range 7.70
6.76 52 Week Range 30.00
Market Cap
24.354M
Previous Close
6.89
Open
6.85
Last Trade
2
@
7.5
Last Trade Time
Financial Volume
US$ 454,909
VWAP
7.2572
Average Volume (3m)
194,286
Shares Outstanding
3,196,103
Dividend Yield
-
PE Ratio
-0.27
Earnings Per Share (EPS)
-27.43
Revenue
15.53M
Net Profit
-87.68M

About Aligos Therapeutics Inc

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's p... Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.aligos.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Aligos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALGS. The last closing price for Aligos Therapeutics was US$6.89. Over the last year, Aligos Therapeutics shares have traded in a share price range of US$ 6.76 to US$ 30.00.

Aligos Therapeutics currently has 3,196,103 shares in issue. The market capitalisation of Aligos Therapeutics is US$22.02 million. Aligos Therapeutics has a price to earnings ratio (PE ratio) of -0.27.

Ask ADVFN Intelligence (AI)

ALGS Latest News

More News

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving...

11 October 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

11 October 2024
Edgar (US Regulatory)

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through...

01 October 2024
GlobeNewswire Inc.

Aligos Therapeutics to Present at Investor Conferences in October

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through...

30 September 2024
GlobeNewswire Inc.

Form 3 - Initial statement of beneficial ownership of securities

27 September 2024
Edgar (US Regulatory)

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through...

24 September 2024
GlobeNewswire Inc.

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat...

19 September 2024
GlobeNewswire Inc.

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving...

19 September 2024
GlobeNewswire Inc.

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving...

13 September 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

07 September 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.61-7.411907654928.238.486.76544127.38887635CS
4-6.25-45.061283345313.8715.36.761042359.54130547CS
12-4.705-38.174442190712.32519.56.7619428612.496298CS
26-17.88-70.117647058825.527.256.7628198413.59076046CS
52-11.86-60.882956878919.48306.7630750916.76459554CS
156-336.88-97.7880986938344.5449.256.7626524051.16666823CS
260-360.88-97.9321573948368.5937.74756.76244079132.20657381CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAMPCAMP4 Therapeutics Corporation
 10.75
(2,587.50%)
378.47k
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
154.23M
NIVFNewGenIvf Group Ltd
US$ 0.98
(63.42%)
58.51M
ATIFATIF Holdings Ltd
US$ 1.235
(58.33%)
3.85M
VERBVerb Technology Company Inc
US$ 7.91
(51.82%)
15.55M
BYUBAIYU Holdings Inc
US$ 0.299
(-35.28%)
10.99M
TURBTurbo Energy SA
US$ 2.1511
(-29.01%)
2.83M
SMSTDefiance Daily Target 1.5X Short MSTR ETF
US$ 7.898
(-23.62%)
984.8k
VEEAVeea Inc
US$ 3.27
(-23.24%)
279.91k
INHDInno Holdings Inc
US$ 3.74
(-22.41%)
243.8k
JTAIJet AI Inc
US$ 0.1009
(23.50%)
340.09M
CDTConduit Pharmaceuticals Inc
US$ 0.116
(13.28%)
270.97M
NVDANVIDIA Corporation
US$ 134.80
(-0.01%)
170.27M
LUXHLuxUrban Hotels Inc
US$ 0.0532
(5.35%)
165.94M
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
154.23M

ALGS Discussion

View Posts
DewDiligence DewDiligence 1 month ago
There were no recent insider stock purchases; rather, the three insider transactions dated 9/6/24 were company grants of stock options to the CEO, CFO, and CCO (read the footnotes):

https://www.sec.gov/Archives/edgar/data/1799448/000161071724000465/xslF345X05/form4.xml (CEO)

https://www.sec.gov/Archives/edgar/data/1799448/000161071724000466/xslF345X05/form4.xml (CFO)

https://www.sec.gov/Archives/edgar/data/1799448/000161071724000464/xslF345X05/form4.xml (CSO)
👍️0
tw0122 tw0122 1 month ago
Insider buy at $11.74 and it finally runs
👍️0
Monksdream Monksdream 3 months ago
ALGS new 52 week low
👍️0
Monksdream Monksdream 4 months ago
ALGS new 52 week low
👍️0
Monksdream Monksdream 4 months ago
ALGS new 52 week low
👍️0
DewDiligence DewDiligence 5 months ago
ALGS 1Q24 results:

https://www.globenewswire.com/news-release/2024/05/07/2877224/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-First-Quarter-2024-Financial-Results.html

Cash at 3/31/24 was $112.7M, down from $135.7M at 12/31/23.

No details on when a phase-2 COVID trial, with support from NIH, will start. The PR merely says, “phase-2 enabling activities…are underway.”

No CC.
👍️0
BurgerKing82 BurgerKing82 7 months ago
Is March 7 a significant catalyst to get in by?
👍️0
TheFinalCD TheFinalCD 10 months ago
$ALGS PHASE 1 NEWS https://finviz.com/quote.ashx?t=ALGS&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/ALGS?a=dbb88c
👍️0
DewDiligence DewDiligence 11 months ago
ALGS 3Q23 results:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500015.html

No CC.
👍️0
DewDiligence DewDiligence 12 months ago
ALGS -15% on warrant-laden $92M financing:

https://www.globenewswire.com/news-release/2023/10/23/2764690/0/en/Aligos-Therapeutics-Announces-92-Million-Private-Placement-Financing.html
👍️0
DewDiligence DewDiligence 1 year ago
ALGS receives $8.5M NIAID grant for clinical development of ALG-097558:

https://finance.yahoo.com/news/aligos-therapeutics-announces-award-8-113000446.html

$8.5M won’t go very far, but I suppose that every little bit helps. ALGS is expected to report data from the phase-1 trial of ALG-097558 in 1H24.
👍️0
Monksdream Monksdream 1 year ago
ALGS new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ALGS new 52 week low
👍️0
DewDiligence DewDiligence 1 year ago
ALG-055009 phase-2a in NASH expected_to_start 1Q24:

https://finance.yahoo.com/news/aligos-therapeutics-announces-ind-clearance-113000003.html

ALG-055009 is a thyroid hormone receptor beta agonist.
👍️0
Monksdream Monksdream 1 year ago
ALGS new 52 week low
👍️0
DewDiligence DewDiligence 1 year ago
ALGS, JNJ reach agreement in principle to settle pending litigation:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001799448/000119312523200617/d538755d8k.htm

The terms will presumably be disclosed when the settlement in finalized.
👍️0
DewDiligence DewDiligence 1 year ago
The relatively low cash burn in 2Q23 was due to ALGS’ slashing R&D expenses by more than half relative to 2Q22 ($17M in 2Q23 vs 2Q22 $35M).
👍️0
DewDiligence DewDiligence 1 year ago
ALGS 2Q23 results—6/30/23 cash=$91M—(down $15M from 3/31/23):

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500975.html

Data from the phase-1 trial of ALG-097558, a SARS-CoV-2 protease inhibitor, are expected in 1H24. The trial, which is being conducted in the UK, is currently in the SAD phase.

No CC.
👍️0
DewDiligence DewDiligence 1 year ago
ALGS HBV data at EASL:

https://www.globenewswire.com/news-release/2023/06/21/2692513/0/en/Aligos-Therapeutics-Presents-Data-from-its-Liver-Disease-Programs-at-the-European-Association-for-the-Study-of-the-Liver-EASL-Congress-2023.html
👍️0
DewDiligence DewDiligence 1 year ago
ALGS +51%/AH on collaboration with Chinese company:

https://finance.yahoo.com/news/aligos-therapeutics-announces-research-collaboration-210500298.html Under the terms of the agreement, Aligos and Amoytop* will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases. Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory while Aligos will retain rest-of-world rights. Aligos will also receive an upfront payment and research collaboration funding and be eligible to receive up to a total of $109 million in development and sales milestone payments for licensed products as well as tiered royalties on net sales. Before the AH pop, ALGS’ enterprise value was deeply negative; after the AH pop, the EV is still negative but less so.

The up-front cash amount is presumably tiny since it wasn’t disclosed.

*Xiamen Amoytop Biotech Company Ltd.
👍️0
DewDiligence DewDiligence 1 year ago
ALGS 1Q23 results—3/31/22 cash=$104M, down from $126M at 12/31/22:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500905.html

ALGS expects to start a phase-1 trial of ALG-097558, a SARS-CoV-2 protease inhibitor, in the UK in mid 2023.

No CC.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS 4Q22 results—12/31/22 cash=$126M—4Q22 cash_burn=$16M:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-210500130.html

ALGS’ COVID protease inhibitor, ALG-097558, is expected to start phase-1 in 2Q23.

No CC.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS “de-prioritizes” HBV program—reduces workforce 10%:

https://finance.yahoo.com/news/aligos-therapeutics-announces-strategic-reprioritization-210500405.html Aligos Therapeutics…today announced a portfolio reprioritization. Aligos’ highest priorities will be focused on rapid advancement of its clinical NASH (ALG-055009) and COVID-19 (ALG-097558) programs as well as maintaining its ongoing NASH oligonucleotide research collaborations with Merck…

Additionally, the Company plans to complete the <=48-week (ALG-000184) and single ascending dose (ALG-125755) cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations.

This portfolio reprioritization is being accompanied by a reduction of the Company’s current workforce of approximately 10%...

…As a result of the portfolio reprioritization, realignment of its workforce, and other cost-saving measures, the Company expects to maintain a strong balance sheet and extend its projected cash runway to the end of 2024. In other words, the HBV program is getting the axe. After completing the early-stage HBV trials in progress, ALGS will offload these assets (if anyone wants them) or simply shut down the program.

The stock is flattish in the AH session.
👍️0
Laster Laster 2 years ago
Might hit $3 today.
Easily moving to $5.
Discussed this on HEPA board at under $1 in December.
Wow.
Yippee.
👍️0
Laster Laster 2 years ago
Beautiful. Will pass $2 today.
Best NASH play out there.
Good luck.
👍️0
Laster Laster 2 years ago
It’s running.
Amazing NASH stock.
$1.20.
$3 in February.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS provides 2023 roadmap:

https://www.globenewswire.com/news-release/2023/01/05/2583624/0/en/Aligos-Therapeutics-on-Track-to-Complete-Phase-2-Enabling-Activities-in-2023-for-its-Clinically-Validated-THR-%C3%9F-Drug-Candidate-for-NASH-ALG-055009.html
👍️0
DewDiligence DewDiligence 2 years ago
ALGS 3Q22 results—9/30/22 cash=$142M—3Q22 cash_burn=$17M:

https://www.globenewswire.com/news-release/2022/11/02/2547039/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Third-Quarter-2022-Financial-Results.html

ALGS’ COVID protease inhibitor, ALG-097558 is expected to start phase-1 in 2Q23.

No CC.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS 2Q22 results—6/30/22 cash=$159.3M—(down from $183M @3/31/22):

https://www.globenewswire.com/news-release/2022/08/04/2492772/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Second-Quarter-2022-Financial-Results.html

Phase-1 for the SARS-CoV-2 protease inhibitor, ALG-097558 has been delayed and is now expected to start in 2023, following a CTA filing in 1Q23. (The prior guidance was for an IND filing in 2H22.)
👍️0
DewDiligence DewDiligence 2 years ago
ALGS—Cash @3/31/22=$183M—$23B burn in 1Q22:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500766.html

Other than the financials, there is no new news. ALGS still plans to start phase-1 for its COVID protease inhibitor in late 2022 or early 2023 (i.e. IND filing in 2H22).

No CC.
👍️0
DewDiligence DewDiligence 3 years ago
ALGS selects lead SARS-CoV-2 PI—phase-1 expected to start in early 2023 (or very late 2022):

https://finance.yahoo.com/news/aligos-therapeutics-selects-drug-candidate-120000412.html

The timing of this program was known from the Leerink webcast two months ago (#msg-167924816), so the only new news is that a lead compound has been selected.
👍️0
DewDiligence DewDiligence 3 years ago
ALGS discontinues another HBV candidate:

https://finance.yahoo.com/news/aligos-discontinues-development-antisense-oligonucleotide-120000830.html Aligos Therapeutics…today announced that it has discontinued development of its drug candidate, ALG-020572, which was being studied in subjects with chronic hepatitis B (CHB).

Dosing in the first CHB cohort of Study ALG-020572-401 (NCT05001022) was stopped after one subject experienced a serious adverse event (SAE) with significant increase in alanine aminotransferase (ALT) following multiple dosing of 210 mg ALG-020572 that resulted in a brief hospitalization. This is one of four CHB subjects in this first cohort who experienced potentially drug-related ALT flares…
👍️0
DewDiligence DewDiligence 3 years ago
ALGS 4Q21 financials—12/31/21_cash=$205.8M:

https://finance.yahoo.com/news/aligos-therapeutics-reports-fourth-quarter-210500703.html

No CC.
👍️0
DewDiligence DewDiligence 3 years ago
Disclosure: I'm long ENTA.
👍️0
DewDiligence DewDiligence 3 years ago
Two takeaways from today's Leerink webcast on ALGS-9711 (oral coronavirus protease inhibitor): 1) ALGS-097111 phase-1 won’t start until 2023 (insofar as the IND is expected to be filed in late 2022); 2) CEO Blatt talked up combination therapy to treat COVID even while insisting compound is “best in class,” which I find curious.
👍️0
DewDiligence DewDiligence 3 years ago
Preclinical data on ALGS-097111 protease inhibitor from 2021 CROI:

https://www.aligos.com/wp-content/uploads/2021/03/CROI21_Science-Spotlight_ID2675_Vandyck_handout_1.pdf
👍️0
DewDiligence DewDiligence 3 years ago
Link to Leerink webcast:

https://wsw.com/webcast/svbleerink67/enta/2640400
👍️0
oxnous oxnous 3 years ago
ALGS--Bungee Jumping

👍️0
DewDiligence DewDiligence 3 years ago
ALGS -40%/PM on_discontinuation_of_lead HBV candidate for_lack_of_efficacy:

https://finance.yahoo.com/news/aligos-halting-further-development-stops-130000126.html
👍️0
DewDiligence DewDiligence 3 years ago
ALGS—(-16%)—sells 5.06M* shares @$19.00—a 20% discount to Monday’s close:

https://finance.yahoo.com/news/aligos-therapeutics-announces-pricing-83-020800387.html

*Assuming exercise of underwriter’s option.
👍️0
DewDiligence DewDiligence 3 years ago
ALGS—(-11%)—presents EASL HBV lineup:

https://finance.yahoo.com/news/aligos-therapeutics-announces-pipeline-upcoming-120000870.html

Nothing in this PR is especially newsworthy, so I’m not sure why the stock is selling off today. Maybe some investors were expecting some kind of big announcement.
👍️0

Your Recent History

NASDAQ
ALGS
Aligos Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved